DK1009732T3 - 1-Amino-alkylcyclohexan NMDA receptor antagonister - Google Patents

1-Amino-alkylcyclohexan NMDA receptor antagonister

Info

Publication number
DK1009732T3
DK1009732T3 DK98939579T DK98939579T DK1009732T3 DK 1009732 T3 DK1009732 T3 DK 1009732T3 DK 98939579 T DK98939579 T DK 98939579T DK 98939579 T DK98939579 T DK 98939579T DK 1009732 T3 DK1009732 T3 DK 1009732T3
Authority
DK
Denmark
Prior art keywords
amino
receptor antagonists
nmda receptor
alkylcyclohexane
alkylcyclohexane nmda
Prior art date
Application number
DK98939579T
Other languages
Danish (da)
English (en)
Inventor
Markus Gold
Wojciech Danysz
Christopher Graham Rap Parsons
Ivars Kalvinsh
Valerjans Kauss
Aigars Jirgensons
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Application granted granted Critical
Publication of DK1009732T3 publication Critical patent/DK1009732T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK98939579T 1997-06-30 1998-06-24 1-Amino-alkylcyclohexan NMDA receptor antagonister DK1009732T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88594497A 1997-06-30 1997-06-30
PCT/EP1998/004026 WO1999001416A2 (en) 1997-06-30 1998-06-24 1-amino-alkylcyclohexane nmda receptor antagonists

Publications (1)

Publication Number Publication Date
DK1009732T3 true DK1009732T3 (da) 2003-09-22

Family

ID=25388050

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98939579T DK1009732T3 (da) 1997-06-30 1998-06-24 1-Amino-alkylcyclohexan NMDA receptor antagonister

Country Status (26)

Country Link
US (1) US6034134A (de)
EP (1) EP1009732B1 (de)
JP (1) JP3963488B2 (de)
KR (1) KR100630506B1 (de)
CN (1) CN1136187C (de)
AR (1) AR010708A1 (de)
AT (1) ATE240936T1 (de)
AU (1) AU724974B2 (de)
CA (1) CA2292558C (de)
CZ (1) CZ293248B6 (de)
DE (1) DE69814878T2 (de)
DK (1) DK1009732T3 (de)
EA (1) EA002254B1 (de)
ES (1) ES2200358T3 (de)
FI (1) FI119809B (de)
GE (1) GEP20032995B (de)
HK (1) HK1029574A1 (de)
HU (1) HU226110B1 (de)
IL (1) IL133235A (de)
NO (1) NO314353B1 (de)
PL (1) PL193237B1 (de)
PT (1) PT1009732E (de)
TW (1) TW593225B (de)
UA (1) UA61962C2 (de)
WO (1) WO1999001416A2 (de)
ZA (1) ZA985678B (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
DE69535758D1 (de) * 1994-08-29 2008-07-03 Univ Wake Forest Lipid-analoge zur behandlung von viralen infektionen
UA72558C2 (uk) * 1999-11-01 2005-03-15 Мерц Фарма Гмбх Унд Ко. Кгаа 1-аміноалкілциклогексанові антагоністи рецептора nmda
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
US6602862B1 (en) * 2000-09-19 2003-08-05 Merz Pharma Gmbh & Co., Kgaa 1-Amino-alkylcyclohexanes as trypanocidal agents
ES2402597T3 (es) 2000-10-18 2013-05-07 Gilead Pharmasset Llc Nucleósidos modificados para el tratamiento de infecciones víricas y proliferación celular anormal
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
US20040266723A1 (en) * 2000-12-15 2004-12-30 Otto Michael J. Antiviral agents for treatment of Flaviviridae infections
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
EP1435974A4 (de) * 2001-09-28 2006-09-06 Idenix Cayman Ltd Verfahren und zusamemnsetzungen zur behandlung des hepatitis-c-virus mit 4'-modifizierten nucleosiden
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
EP2799442A1 (de) 2002-06-28 2014-11-05 IDENIX Pharmaceuticals, Inc. Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
CA2494340C (en) * 2002-08-01 2012-01-24 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
KR100852834B1 (ko) 2002-10-24 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP1631274A4 (de) * 2003-05-27 2007-03-28 Forest Laboratories Kombination eines nmda-rezeptor-antagonisten und eines selektiven serotonin-wiederaufnahmehemmers zur behandlung von depressionen und anderen stimmungsstörungen
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
AU2004258750A1 (en) 2003-07-25 2005-02-03 Centre National De La Recherche Scientifique -Cnrs Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
US20070082956A1 (en) * 2003-07-28 2007-04-12 Merz Pharma Gmbh & Co. Kgaa The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity.
CA2540921A1 (en) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic ass peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
AU2005265031A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP2397122B1 (de) 2004-06-17 2014-05-14 Merz Pharma GmbH & Co. KGaA Formulierungen aus Neramexan-Dosierformen
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
AU2005256963A1 (en) * 2004-06-23 2006-01-05 Centre National De La Recherche Scientifique 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PL3109244T3 (pl) 2004-09-14 2019-09-30 Gilead Pharmasset Llc Wytwarzanie 2'fluoro-2'-alkilo-podstawionych lub innych ewentualnie podstawionych rybofuranozylopirymidyn i puryn oraz ich pochodnych
TW200621677A (en) * 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CA2607600A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
PL2042480T3 (pl) 2006-07-18 2013-09-30 Astellas Pharma Inc Pochodna aminoindanu lub jej sól
ATE494289T1 (de) 2006-08-04 2011-01-15 Merz Pharma Gmbh & Co Kgaa Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008219622A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
TW200916091A (en) * 2007-06-08 2009-04-16 Merz Pharma Gmbh & Amp Co Kgaa Neramexane for the treatment of nystagmus
AU2008272964A1 (en) * 2007-06-29 2009-01-08 Emory University NMDA receptor antagonists for neuroprotection
EP2018854A1 (de) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Neuartige Kombination von Neramexan zur Behandlung neurodegenerativer Erkrankungen
MX2010002733A (es) * 2007-09-12 2010-04-09 Merz Pharma Gmbh & Co Kgaa Terapia de intervalo para el tratamiento de tinnitus.
RU2438658C2 (ru) * 2007-09-12 2012-01-10 Мерц Фарма Гмбх Унд Ко. Кгаа Производные 1-аминоалкилциклогексана для лечения кохлеарного тиннитуса
EP2090576A1 (de) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-Pyrazolo[1,5-a]pyridin-Verbindungen, Verfahren zu ihrer Herstellung und Verwendung als Modulatoren des Metabotropen Glutamatrezeptoren (mGluR)
EP2085398A1 (de) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2111858A1 (de) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Neue Behandlung für Morbus Alzheimer
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
KR20110065440A (ko) 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
CA2737335C (en) * 2008-12-19 2013-10-01 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
AR074977A1 (es) 2008-12-23 2011-03-02 Pharmasset Inc Sintesis de nucleosidos de purina
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8784847B2 (en) * 2009-04-17 2014-07-22 Merz Pharma Gmbh & Co. Kgaa Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US20130123541A1 (en) * 2009-06-29 2013-05-16 Merz Pharma Gmbh & Co. Kgaa Method of preparing 3,3,5,5-tetramethylcyclohexanone
CA2765741A1 (en) 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane
EP2448911A1 (de) 2009-06-29 2012-05-09 Merz Pharma GmbH & Co. KGaA Verfahren zur herstellung von 1-chloracetamid-1,3,3,5,5-pentamethylcyclohexan
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011035924A1 (en) * 2009-09-28 2011-03-31 Merz Pharma Gmbh & Co. Kgaa Method of preparing neramexane or a salt thereof
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
EP2513113B1 (de) 2009-12-18 2018-08-01 Idenix Pharmaceuticals LLC Auf 5,5-kondensiertem arylen oder heteroarylen basierende hepatitis-c-virus-hemmer
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CA2795054A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
BR112012032398A2 (pt) * 2010-06-18 2016-11-08 Merz Pharma Gmbh & Co Kgaa composição farmacêutica para aplicação tópica à pele de um paciente e kit
WO2012048235A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
WO2012098000A1 (en) 2011-01-20 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (de) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
KR20140063657A (ko) 2011-08-03 2014-05-27 사이세리스 Hcv 면역요법
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US10513534B2 (en) 2012-10-08 2019-12-24 Idenix Pharmaceuticals Llc 2′-chloro nucleoside analogs for HCV infection
EP2909223B1 (de) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinukleotidverbindungen für hcv-infektion
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
EP2938624A1 (de) 2012-11-14 2015-11-04 IDENIX Pharmaceuticals, Inc. D-alaninester von sp-nukleosidanalogon
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
EP2981542B1 (de) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluor-nukleoside zur behandlung von hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (de) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichlor- und 2'-fluor-2'-chlor-nukleosidanaloga für hcv-infektion
EP3083654A1 (de) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or-nukleoside zur behandlung von hcv
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
EP3131914B1 (de) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
EP3568388A4 (de) 2017-01-10 2020-10-14 Owen-Barry Pharmaceuticals Inc. Antikonvulsive verbindungen
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
WO2023154014A1 (en) 2022-02-08 2023-08-17 Sahin Fikret Nmdar antagonists prevent ageing and aging-associated conditions and diseases through increasing 20s proteasome activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541181A1 (de) * 1985-11-21 1987-05-27 Basf Ag Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases

Also Published As

Publication number Publication date
CN1266423A (zh) 2000-09-13
IL133235A (en) 2004-02-19
ATE240936T1 (de) 2003-06-15
CA2292558A1 (en) 1999-01-14
EP1009732B1 (de) 2003-05-21
PT1009732E (pt) 2003-10-31
CA2292558C (en) 2006-09-19
FI119809B (fi) 2009-03-31
US6034134A (en) 2000-03-07
HU226110B1 (en) 2008-04-28
DE69814878D1 (de) 2003-06-26
EP1009732A2 (de) 2000-06-21
CZ457199A3 (cs) 2000-06-14
WO1999001416A3 (en) 1999-08-19
PL193237B1 (pl) 2007-01-31
AU724974B2 (en) 2000-10-05
NO314353B1 (no) 2003-03-10
AR010708A1 (es) 2000-07-12
UA61962C2 (uk) 2003-12-15
PL337809A1 (en) 2000-09-11
EA002254B1 (ru) 2002-02-28
NO996548D0 (no) 1999-12-29
HUP0100266A3 (en) 2003-07-28
JP2002511873A (ja) 2002-04-16
GEP20032995B (en) 2003-06-25
NO996548L (no) 2000-02-28
EA200000080A1 (ru) 2000-08-28
JP3963488B2 (ja) 2007-08-22
KR100630506B1 (ko) 2006-09-29
CZ293248B6 (cs) 2004-03-17
ZA985678B (en) 2000-01-10
DE69814878T2 (de) 2004-05-19
CN1136187C (zh) 2004-01-28
WO1999001416A2 (en) 1999-01-14
IL133235A0 (en) 2001-03-19
HUP0100266A2 (hu) 2002-05-29
ES2200358T3 (es) 2004-03-01
FI19992801A (fi) 1999-12-29
KR20010013738A (ko) 2001-02-26
TW593225B (en) 2004-06-21
AU8804298A (en) 1999-01-25
HK1029574A1 (en) 2001-04-06

Similar Documents

Publication Publication Date Title
DK1009732T3 (da) 1-Amino-alkylcyclohexan NMDA receptor antagonister
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
NO972016D0 (no) Indolyl-Y-reseptorantagonister
DE69734833D1 (de) Vitronektin rezeptor antagonisten
DE69833073D1 (de) CCR-3-Rezeptor-Antagonisten
ATE280157T1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
NO993586L (no) K-8 reseptor antagonister
FI960953A (fi) Endoteliinireseptoriantagonisteja
NO993350D0 (no) Vitronectin-reseptor-antagonister
ID16742A (id) Antagonis reseptor endotelin
ID24726A (id) Antagonis-antagonis reseptor trombin
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
NO950606D0 (no) Adhesjonsreseptor-antagonister
ID24162A (id) Antagonis-antagonis reseptor vitronektin
ID26223A (id) Antagonis reseptor vitronektin
ID28811A (id) Antagonis reseptor vitronektin
TR199501389A2 (tr) Adesyon reseptörü antagonistleri (karsitlari).
ATE303370T1 (de) Il-8 rezeptor antagonisten
DE69616364D1 (de) Endothelinrezeptorantagonisten
ATE341324T1 (de) Endothelin rezeptor antagonisten
ID22978A (id) Antagonis reseptor endotelin
DK1011716T5 (da) Neuromedin B-receptor-antagonister
DE69830671D1 (de) Integrin-rezeptor-antagonisten
TR199601082A3 (tr) Entegrin reseptör antagonistleri.
SE9703745D0 (sv) New receptors